Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November, 2022

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 15, 2022, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended November 30, 2022, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:



   Ordinary Shares
   Volume Weighted
Average Price Paid
per Ordinary Share
   Highest Price Paid    Lowest Price Paid
November 1, 2022    37,358    241.12p    242.50p    233.00p
November 2, 2022    19,275    248.45p    248.50p    243.50p
November 3, 2022    28,771    242.46p    242.50p    242.00p
November 4, 2022    32,022    247.65p    250.00p    244.50p
November 7, 2022    25,351    245.83p    248.50p    243.00p
November 8 2022    24,786    246.63p    248.50p    242.00p
November 9, 2022    22,493    242.70p    247.00p    238.50p
November 10, 2022    21,690    239.84p    243.00p    237.00p
November 11, 2022    20,635    239.81p    247.50p    237.00p
November 14, 2022    19,635    240.55p    242.00p    238.00p
November 15, 2022    18,246    239.73p    242.00p    236.00p
November 16, 2022    18,584    236.83p    240.00p    234.00p
November 17, 2022    18,045    237.90p    243.50p    236.00p
November 18, 2022    17,427    239.70p    241.00p    236.00p
November 21, 2022    342    249.58p    250.00p    249.00p

During the month ended November 30, 2022, the Company repurchased an aggregate of 324,660 Ordinary Shares. As of November 30, 2022, the Company’s issued share capital was 289,161,653 shares, 10,595,347 of which were held in treasury, resulting in total voting rights in the Company of 278,566,306 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

November 1, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4565178.html

November 2, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4566680.html

November 3, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4568103.html

November 4, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4569729.html

November 7, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4571158.html

November 8, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4572762.html

November 9, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4574222.html

November 10, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4575815.html

November 11, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4577418.html

November 14, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4578981.html

November 15, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4580448.html

November 16, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4582101.html

November 17, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4583606.html

November 18, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4585091.html

November 21, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4586559.html


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: December 2, 2022   By:  

/s/ Daphne Zohar

    Name:   Daphne Zohar
    Title:   Chief Executive Officer